Dr. Awais Javed M.D.

Recommended Articles

• Meet Josh Llewellyn-Jones, a Cystic Fibrosis Hero

  In many respects, Josh Llewellyn-Jones is a normal 30-year-old guy. As with many men his age, he’s into physical stamina and setting personal records. Referred to as a “fitness fanatic”, Josh has recently completed a successful 24-hour fitness challenge. The only competitor was Josh. And, he...

• Pathogens that Cause Pneumonia

  The pathogens involved in pneumonia are bacteria, virus, fungus, rare parasites, and other microorganisms. Virus is the most common cause of pneumonia among babies and children. Adults with weak immune systems are vulnerable to bacterial pneumonia.Pneumonia Causing pathogens:The pathogens that cause...

• What Is Paroxysmal Atrial Fibrillation?

  What Is Paroxysmal Atrial Fibrillation?Paroxysmal is a condition derived from atrial fibrillation. Atrial fibrillation (AFib) refers to abnormal heartbeats. These impulses are not just irregular heartbeats, but appear as vibrations in the atria chamber of the heart. Once a person suffers from the...

• An Open Letter to Parents of Children with Cystic Fibrosis

  A columnist with Cystic Fibrosis News Today recently opened up about what his life with cystic fibrosis has been like. He is a deaf 24-year-old named Brad Dell, and he loves everything about his life. Instead of letting the disease ruin his life, he has chosen to be thankful for everything that he...

• Preventing Exacerbations of COPD

  According to a statistic, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD) around the world. More than 3 million people have died because of COPD in 2005, which corresponds to 5 percent of all deaths globally. This puts COPD as one of the major causes of...

• FDA Approves Orkambi to Treat Young Children with Cystic Fibrosis

  Orkambi is an oral drug developed by Vertex Pharmaceuticals and approved by the United States Food and Drug Administration (FDA) for the treatment of cystic fibrosis (CF) in certain patient groups. It is the second drug to be approved for use in patients with CF, after Kalydeco. ...